REG - Venture Life Group - Results - clinical trial led by Cardiff University

Venture LifeAnnouncement

21/02/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220221:nRSU2074Ca&default-theme=true

RNS Number : 2074C  Venture Life Group PLC  21 February 2022

 

21st February 2022

 

VENTURE LIFE GROUP PLC

("Venture Life" "VLG" or the "Company")

UK-led clinical trial suggests certain types of mouthwash can inactivate
SARS-CoV-2 in the mouth for up to 1 hour

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, announced on 24(th) August
2020 its involvement in a UK-led clinical trial, with one of its key oral care
brands containing Cetylpyridinium Chloride ("CPC") technology, on patients
with COVID-19.

Today, results of a small-scale clinical trial led by Cardiff University
indicate that a mouthwash containing the antimicrobial agent CPC can
inactivate SARS-CoV-2 in the mouth for up to 1 hour.

78 patients were recruited for the trial, with 27 patients having 'live' virus
in their saliva. The results, published on preprint server medRxiv, showed
that a 30-second rinse with a CPC-based mouthwash in seven hospitalised
COVID-19 patients eliminated the virus in the saliva by >99.99% at one
minute, and by >99.8% at 60 minutes. In three out of the seven patients
(around 40%) no live virus was detected at any time after the initial rinse.
 

The CPC-based mouthwash used in the Cardiff University study was one of a
number of mouthwash formulations tested, alongside a saline control.

Further large-scale clinical trials are now needed to establish whether
CPC-based mouthwashes could provide a simple, yet effective preventative
measure to help in the fight against COVID-19, for example, as part of oral
hygiene measures in hospitals or other healthcare settings.

The clinical study was part-funded by Venture Life Group, the manufacturer of
the CPC-based mouthwash used, but there was no input in design, data analysis
or drafting of the research paper.   In addition to being published on
medRxiv, the results have been submitted to a journal for peer review and we
await the outcome of this process.

 

Link to research paper

https://medrxiv.org/cgi/content/short/2022.02.16.22270842v1
(https://medrxiv.org/cgi/content/short/2022.02.16.22270842v1)

 

 Venture Life Group PLC                              +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cenkos Securities plc (Nomad and Joint Broker)      +44 (0) 20 7397 8900
 Michael Johnson/Russell Kerr (Sales)

 Stephen Keys/Camilla Hume (Corporate Finance)

 Singer Capital Markets (Joint Broker)               +44 (0) 20 7496 3000
 Jonathan Dighe (Sales)

 Shaun Dobson/Alaina Wong (Corporate Finance)

About Venture Life (www.venture-life.com (http://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. The Group's product portfolio includes key products such as
Dentyl mouthwash and the UltraDEX oral care range, as well as the Balance
Active range in the area of women's intimate healthcare, the Lift and Glucogel
product ranges for hypoglycaemia, products for fungal infections and
proctology, and dermo-cosmetics for addressing the signs of ageing. Its
products are sold in over 90 countries worldwide and the Company has
operations in the UK, Italy, The Netherlands and Sweden.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples. In the UK and The Netherlands these are supplied direct by the
company to retailers, elsewhere they are supplied by the Group's international
distribution partners.

Through its two Development & Manufacturing operations in Italy and
Sweden, the Group also provides development and manufacturing services to
companies in the medical devices and cosmetic sectors.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPURGPUPPPGU